Accessibility Menu
TG Therapeutics Stock Quote

TG Therapeutics (NASDAQ: TGTX)

$35.22
(0.3%)
+0.10
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$35.22
Daily Change
(0.3%) +$0.10
Day's Range
$34.82 - $35.52
Previous Close
$35.22
Open
$35.1
Beta
1.87
Volume
1,153,696
Average Volume
2,191,646
Market Cap
5.6B
Market Cap / Employee
$35.12M
52wk Range
$22.61 - $46.48
Revenue
-
Gross Margin
0.87%
Dividend Yield
N/A
EPS
$0.37
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

TG Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TGTX+50.66%+28.98%+5.22%+2,991%
S&P+14.84%+96.04%+14.41%+436%

TG Therapeutics Company Info

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$141.15M92.1%
Gross Profit$122.15M87.7%
Gross Margin86.54%-2.1%
Market Cap$28.57B107.8%
Market Cap / Employee$81.16M0.0%
Employees3520.0%
Net Income$28.19M309.8%
EBITDA$34.90M292.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$129.13M55.7%
Accounts Receivable$231.52M176.9%
Inventory155.291.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$252.63M127.1%
Short Term Debt$1.09M-16.5%

Ratios

Q2 2025YOY Change
Return On Assets10.95%-19.8%
Return On Invested Capital-58.98%45.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$7.39M33.6%
Operating Free Cash Flow$7.44M34.3%

Valuation

MetricQ2 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings29.65215.62161.6096.1839.43%
Price to Book94.81122.01138.17119.9539.68%
Price to Sales14.2014.6616.6112.8857.52%
Price to Tangible Book Value94.81122.01138.17119.9538.99%
Price to Free Cash Flow TTM109.6541.82-
Enterprise Value to EBITDA293.80158.81736.97167.68-45.44%
Free Cash Flow Yield0.9%2.4%-
Return on Equity-8.0%12.2%19.7%26.6%-69.66%
Total Debt$253.81M$253.72M$253.71M$253.72M125.45%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.